Eeva Moilanen, MD, PhD, is Professor of Pharmacology at the University of Tampere, Faculty of Medicine and Life Sciences, Tampere, Finland. She is responsible for teaching pharmacology and clinical pharmacology at the Medical Curriculum at the University; in research, she is running The Immunopharmacology Research Group with 30 members affiliated at the University of Tampere and Tampere University Hospital. Professor Moilanen had her doctoral and post-doctoral education in Finland (at the University of Tampere, in Professor Heikki Vapaatalo’s laboratory) and in U.K. (at the Wellcome Research Laboratories, in Professor Salvador Moncada’s research group).
Professor Moilanen’s research is focusing on the mechanisms of inflammation aiming to identify and validate novel anti-inflammatory mechanisms, treatment targets and molecules especially in osteoarthritis and rheumatoid arthritis. Previously, the focus was mainly in the regulation of eicosanoids and in the nitric oxide / iNOS pathway while more recently the interest has turned to wider gene expression signatures characteristic of different phenotypes of inflammation. The most recent research projects aim to understand the role of adipokines as well as MAP kinase / MAP kinase phosphatase pathways in arthritis; and the TRPA1 ion channel mediated signals in the pathogenesis of inflammation and in the inflammatory pain.
Professor Moilanen is a Member of the Board of Directors, Osteoarthritis Research Society International (OARSI) and a Member of the Executive Committee, International Union of Basic and Clinical Pharmacology (IUPHAR). She has served as the President of the Federation of European Pharmacological Societies (EPHAR), and the Finnish Pharmacological Society and the Finnish Osteoarthritis Research Society. Professor Moilanen has supervised 22 PhD students and published over 300 peer-reviewed scientific articles.
Eeva lives in Tampere with her husband Teemu, orthopedic surgeon. She is a mother of three adult sons and in her leisure time enjoys trekking and skiing.